GlassScriptPhysician profile
Mona Amirkhani
NPI 1831785237
$2,901.22
in general payments reported to CMS, 2019-2025
20 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.01 · 2022: $444 · 2023: $645 · 2024: $638 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,087.77 | 2021-2025 | |
| Lilly USA, LLC | $396.18 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $342.79 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $195.38 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $181.01 | 2024-2025 | |
| Amgen INC. | $161.33 | 2022-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $102.15 | 2024-2025 | Zoryve |
| Exact Sciences Corporation | $87.13 | 2023-2025 | Cologuard Collection Kit |
| Indivior INC. | $49.63 | 2025 | Sublocade |
| Lundbeck LLC | $40.62 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $39.15 | 2025 | Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $31.95 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $31.16 | 2022-2024 | Contrave |
| Ironwood Pharmaceuticals, INC | $26.91 | 2025 | |
| Sumitomo Pharma America, INC. | $24.28 | 2025 | Gemtesa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22.62 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $22.25 | 2024 | Shingrix, Arexvy |
| Pfizer INC. | $21.94 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.42 | 2022 | |
| Acella Pharmaceuticals, LLC | $17.55 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Amirkhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.